01—Abstract
Summary
Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) announced its second quarter financial results for the period ended June 30, 2024, via a press release filed on August 1, 2024.
This 8-K filing primarily serves to furnish this press release, which contains the company's operational and financial performance for the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial results, including revenue, profitability, and any forward-looking statements or guidance.
02—Key points
Key Highlights
- Moderna has filed an 8-K reporting its Q2 2024 financial results.
- The financial results are detailed in a press release furnished as Exhibit 99.1.
- The filing incorporates the press release by reference.
- This report is furnished, not deemed 'filed' for certain sections of securities law, limiting liability under Section 18 of the Exchange Act.
- Investors need to consult Exhibit 99.1 for specific financial figures and operational details.
- The Cover Page Interactive Data File is also included as Exhibit 104.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The primary purpose of this 8-K filing is to formally announce and furnish Moderna, Inc.'s financial results for the second quarter ended June 30, 2024, as detailed in a press release (Exhibit 99.1).
Where can I find the detailed financial results for Q2 2024?
The detailed financial results, including revenue, expenses, and profitability for the second quarter ended June 30, 2024, are located in the press release furnished as Exhibit 99.1 to this 8-K filing.
What is the significance of the information being 'furnished' versus 'filed'?
The distinction means that while the information is publicly disclosed, it is not subject to the same level of liability under Section 18 of the Securities Exchange Act of 1934 as information that is formally 'filed'. This is a common practice for earnings press releases.
Does this filing provide updated financial guidance for the remainder of 2024?
This 8-K filing itself does not contain financial guidance. Investors should review the content of the furnished press release (Exhibit 99.1) for any potential updates or commentary on forward-looking financial guidance provided by Moderna.
04—Continue